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Interstitial fibrosis in hypercholesterolemic rats: Role of oxidation,
matrix synthesis and proteolytic cascades. Uninephrectomized rats with
diet-induced hypercholesterolemia develop interstitial inflammation and
fibrosis after 8 to 12 weeks. Fibrosis has been associated with the
accumulation of lipid peroxidation products within the tubulointerstitium,
along with increased renal mRNA levels for transforming growth factor
beta-1 (TGF-b1), some matrix proteins, and the tissue inhibitor of
metalloproteinases (TIMP-1). However, mRNA levels for urokinase-type
plasminogen activator (uPA) have been found to be decreased. The
purpose of the present study was to determine whether antioxidant
therapy could attenuate interstitial fibrosis in hypercholesterolemic rats
and to determine changes in the pattern of renal gene expression induced
by antioxidant therapy. Three groups of uninephrectomized rats were
studied after 12 weeks of feeding standard rat chow, an atherogenic diet
(standard chow plus 4% cholesterol/1% cholic acid), or an atherogenic
diet supplemented with high doses of the antioxidants probucol and
vitamin E. Rats fed the atherogenic diet developed hypercholesterolemia
and a 56% increase in total kidney collagen compared with rats fed
standard chow. In comparison, the hypercholesterolemic rats treated with
antioxidants had normal levels of renal lipid peroxidation products and a
normal kidney collagen content. In contrast, there were no significant
differences in urinary albumin excretion rates or the number of interstitial
macrophages between the two hypercholesterolemic groups. Compared
with the untreated hypercholesterolemic group, antioxidant therapy in-
duced significant reductions in renal mRNA levels for procollagen III (to
60% of untreated levels), collagen IV (60%), and TIMP-1 (20%), while
uPA levels were significantly increased (to 210%). Paradoxically, antioxi-
dant therapy was associated with a significant increase in renal TGF-b1
mRNA levels (to 150%), although TGF-b1 protein expression shifted
from interstitial to tubular epithelial cells in predominance. The results of
the present study demonstrate the efficiency of antioxidant therapy in
preventing renal interstitial fibrosis in hypercholesterolemic rats with a
single kidney. Based on changes in renal gene expression at the mRNA
level, impaired matrix protein synthesis and increased intrarenal activity of
the metalloproteinases and uPA/plasmin may play a role in the attenua-
tion of fibrosis.
Progressive renal failure is characterized histologically by the
accumulation of extracellular matrix proteins within the renal
interstitium and progressive tubular atrophy. This final common
pathway of progressive tubulointerstitial damage predicts the
degree of renal functional impairment and long-term prognosis.
The factors that have been implicated in the initiation of this
cascade are numerous and include cytokines, growth factors,
angiotensin II, endothelin, complement proteins, proteolytic en-
zymes, iron, reactive oxygen metabolites, phosphate, and mechan-
ical factors related to tubular obstruction [reviewed in 1]. Abnor-
malities in lipid metabolism may also play a role in progressive
renal disease, particularly at the level of the glomerulus [2].
However, there is increasing evidence that lipoprotein abnormal-
ities associated with renal disease may also play an active role in
progressive tubulointerstitial disease. This hypothesis first gained
popularity in 1982 when Moorhead and colleagues [3] suggested
that lipoproteins produced by the liver in response to proteinuria
might contribute to progressive renal disease.
In studies of animal models of hypercholesterolemia caused by
genetic factors (such as in obese Zucker rats) or induced by high
dietary cholesterol, histologic evidence of tubulointerstitial dis-
ease has occasionally been reported [4–8]. Hyperlipidemia wors-
ens tubulointerstitial damage in rats with chronic anti-Thy-1
glomerulonephritis [9]. We recently reported that uninephrecto-
mized rats fed a high cholesterol diet develop tubulointerstitial
disease, but that in the absence of pre-existing renal disease the
process appears to be indolent [10]. It took eight weeks before a
significant interstitial infiltrate of macrophages could be detected;
significant interstitial fibrosis did not develop until 12 weeks. In
that study we speculated that oxidized low-density lipoprotein
(LDL) may play an active role in mediating the tubulointerstitial
disease, as the level of renal lipid peroxidation products was
significantly increased and oxidized LDL was detected within
tubular and interstitial cells.
Once oxidized, LDL is not eliminated by the hepatic native
LDL receptor system. Instead, these modified lipoproteins bind to
a family of scavenger receptors that includes macrophage type-I
and type-II class A scavenger receptors, CD36, scavenger receptor
BI, macrosialin/CD68, MARCO and FcgRII [11–18]. Macro-
phages are an important source of scavenger receptors and are
thought to be the precursor of the lipid-laden “foam cell” that
characterizes the early atherosclerotic lesion. Renal tubular cells
are able to internalize oxidized LDL, although the specific
receptor pathways involved are not yet known. Uptake of oxidized
LDL by scavenger receptors may trigger a cascade of responses
leading to fibrogenesis. The exact mechanisms whereby LDL is
oxidized in the kidney remain to be explained and are likely
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multifactorial. One possibility is a superoxide-dependent mecha-
nism, a pathway of LDL oxidation that has been identified using
cultured human renal tubular cells [19].
The molecular pathways that lead to interstitial fibrosis once
LDL is oxidized within the kidney are not yet clear. Our previous
study of uninephrectomized hypercholesterolemic rats identified
several candidates. Modest but significant increases in renal
mRNA levels for procollagen a1(I) and procollagen a1(III)
suggested that matrix protein synthesis rates were increased.
Matrix protein synthesis could be a direct consequence of LDL
oxidation or an indirect one regulated by the production of
fibrogenic cytokines such as TGF-b1. In our initial study, renal
TGF-b1 mRNA levels were significantly elevated and bioactive
TGF-b1 protein was identified in both tubular and interstitial
cells. Our previous study suggested that in addition to increased
matrix protein synthesis, impaired matrix protein turnover also
contributed to interstitial fibrosis. Two proteolytic pathways were
implicated. The first is the metalloproteinase family [20]. The
metalloproteinases are a group of enzymes characterized in part
by zinc-dependent enzyme activity. Together these enzymes are
able to degrade virtually all matrix proteins. Members of this
family include gelatinases, collagenases, and stromelysins. En-
zyme activity can be blocked by the non-covalent interaction of
latent and/or active enzymes with tissue inhibitors of metallopro-
teinases (TIMP). The renal disease that developed in the hyper-
cholesterolemic rats was characterized by up-regulated expression
of TIMP-1. The second proteolytic pathway is the plasminogen
activator/plasmin pathway [21]. Renal tubules constitutively pro-
duce significant quantities of urokinase-type plasminogen activa-
tor (uPA). During the three-month study period, renal uPA
mRNA levels were down-regulated, while expression of plasmin-
ogen activator inhibitor-1 (PAI-1) was unchanged, which are
changes that would predict decreased intrarenal generation of
plasmin. Plasmin has important effects on matrix turnover by
virtue of its ability to degrade selected matrix proteins, but more
importantly to activate latent metalloproteinases.
The present study was designed to to determine whether
antioxidant therapy could attenuate interstitial fibrosis in hyper-
cholesterolemic rats and to determine changes in the pattern of
renal gene expression induced by antioxidant therapy.
METHODS
Experimental design
Thirty-nine female Sprague-Dawley rats weighing 100 to 120 g
were purchased from Charles River Breeding Laboratories (Wil-
mington, MA, USA). We performed a left nephrectomy on each
animal five days before the study began.
To examine the effects of antioxidant therapy on renal intersti-
tial fibrosis, three groups of seven animals were studied. The
control group was fed standard rat chow containing 270 mg
cholesterol per kilogram (Purina Mills Inc., Richmond, IN, USA).
The high-cholesterol group was fed standard rat chow supple-
mented with 4% cholesterol and 1% cholic acid (Purina Test
Diets). The high-cholesterol/antioxidant group was fed the same
high-cholesterol diet supplement, with the addition of vitamin E
(alpha-tocopherol acetate, 150 IU per 30 mg) and 2% probucol
powder (kindly provided by Marion Merrell Dow Inc., Cincinnati,
OH, USA). Vitamin E and probucol were added to the high-
cholesterol diet and prepared as pellets of chow by Purina Mills
Inc. A combination of two high-dose antioxidants was used
because we had just completed a study in rats with acute nephrotic
syndrome and found that neither supplement alone had a signif-
icant anti-fibrotic effect [22]. The rats were housed individually in
metabolic cages at 8 and 12 weeks to collect spontaneously voided
urine over a 24 hour period. At 12 weeks all animals were killed
by exsanguination under general anesthesia by inhalation of
nitrous oxide, oxygen, and enflurane. The right kidney was
carefully decapsulated and weighed (wet weight). The kidney was
divided in half longitudinally. One half was carefully weighed,
frozen in liquid nitrogen, and stored at 270° for total collagen
measurement. The other half of the kidney was divided into two
pieces, one of which was snap-frozen in isopentane pre-cooled in
liquid nitrogen for subsequent immunostaining. The final piece
was snap-frozen in liquid nitrogen and stored at 270°C until RNA
extraction.
To measure renal lipid peroxidation products, a second study
was performed. Eighteen uninephrectomized female Sprague-
Dawley rats were divided into three groups of six animals each,
fed the control diet, the high-cholesterol diet, and the high-
cholesterol/antioxidant diet, respectively. The animals were killed
as described above at the end of five weeks. This earlier time point
was used as our previous study showed little difference in the
degree of elevation of renal peroxidation products at 4, 8 and 12
weeks [10]. The right kidney was removed, decapsulated, frozen in
liquid nitrogen, and stored at 270°C for measurement of lipid
peroxidation products.
Biochemical studies
Urinary albumin concentrations were measured by radial im-
munodiffusion according to our previously described methods
[23]. Plasma creatinine, total cholesterol and triglyceride levels
were measured on individual samples of heparinized blood ob-
tained when the rats were exsanguinated. Plasma vitamin E levels
were measured on three randomly selected animals from each of
the three dietary groups by a liquid chromatographic method
modified from that of Catignani and Bieri [24].
Total kidney collagen was calculated as previously described
[25] based on measurements of the hydroxyproline concentration
in kidney homogenates according to the technique of Kivirikko,
Laitinen and Prockop [26]. Collagen was assumed to contain
12.7% hydroxyproline by weight. Final results, based on the wet
weight of the kidney, were expressed as milligrams of collagen per
kidney. Renal peroxidation products were assessed using thiobar-
bituric acid assay to measure the renal malondialdehyde content
according to the methods of Ohkawa, Ohishi and Yagi [27].
Renal immunofluorescence studies
The number of interstitial macrophages expressing the ED-1
cytoplasmic marker (Serotec, Oxford, UK) was determined on
acetone-fixed kidney cryosections 3 mm thick using the dual
fluorochrome labeling and enumeration technique previously
described [10].
The accumulation of interstitial matrix proteins in the renal
interstitium was assessed semiquantitatively, as previously de-
scribed [28]. In brief, at least 50 random interstitial fields of the
cortical interstitium were evaluated by fluorescence microscopy
for evidence of increased staining for interstitial matrix proteins.
Each field was defined as the area contained within a 10 mm 3 10
mm eyepiece grid (magnification 3400). Each field was evaluated
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by the investigator (A.E.) who was blinded to the animal group at
the time of the evaluation. The range of normal staining for the
matrix protein of interest was first determined for three control
animals. Each of the 50 fields was then determined to have either
a normal or an increased area of interstitial staining. Equivocal
fields were assigned to the normal group. For each animal the
results were expressed as the percent of interstitial fields with a
definite increase in the area stained for each specific interstitial
matrix protein. The primary antibodies used were: sheep anti-
human collagen I; goat anti-human collagen III (Southern Bio-
technology Associates, Birmingham, AL, USA); rabbit anti-hu-
man tenascin (a gift from Dr. H. Erickson, Duke University, NC,
USA); and a murine monoclonal antibody to human extracellular
domain A (EDA1) fibronectin, an alternatively spliced form of
fibronectin (a gift from Dr. L. Zardi, Institute Nazionale perla
Rererca sul Concro, Italy).
Tissue sections from each animal group were evaluated by
indirect immunofluorescence staining for the pattern of expres-
sion of TIMP-1 (rabbit anti-bovine TIMP-1, a gift from Dr. Y.A.
DeClerk, Children’s Hospital of Los Angeles, Los Angeles, CA,
USA), uPA (rabbit anti-human uPA from American Diagnostica
Inc., Greenwich, CT, USA), and TGF-b1 [rabbit anti-TGF-b1
(anti-LC) antibody, a gift from Dr. K. Flanders, National Insti-
tutes of Health, Bethesda, MD, USA]. The secondary antisera for
detecting polyclonal antibodies were fluorescein isothiocyanate
(FITC)–conjugated goat anti-rabbit IgG and FITC-conjugated
rabbit anti-goat IgG antisera (Chemicon International Inc., Te-
mecula, CA, USA). The secondary antiserum for detecting mu-
rine monoclonal antibodies was FITC-conjugated goat anti-
mouse IgG (Zymed Laboratories Inc., San Francisco, CA, USA).
The FITC-conjugated antisera were absorbed with normal rat
plasma; lack of staining showed them to be nonreactive with
control kidney sections. Code numbers were used to blind the
investigator to the animal group in each case.
We isolated total renal cortical RNA according to the guani-
dinium isothiocyanate–cesium chloride method of Chirgwin and
co-workers [29], separated it by electrophoresis in a 1% formal-
dehyde agarose gel, transferred it to a nylon-membrane Gene
Screen (NEN Research Products, Boston, MA, USA), and probed
it with 32P-labeled dCTP. For these studies, RNA samples of 10
mg from each animal in the high-cholesterol and the high-
cholesterol/antioxidant groups were loaded onto separate wells on
the same gel to permit direct comparison of results. We obtained
autoradiographs and quantified the bands by laser densitometry.
The density reading of each band on the autoradiograph was
adjusted for any RNA-loading inequality, as previously described
[10]. To simplify the presentation of the data, final results were
expressed as the ratios of mean densitometric scores.
The cDNA probes used were: rat a1(I) procollagen (supplied
by Dr. S. Thorgeirsson, National Cancer Institute, Bethesda, MD,
USA); murine a1(III) procollagen (supplied by Dr. B. deCrom-
brugghe, Anderson Cancer Center, The University of Texas,
Houston, TX, USA) [30]; murine a2(IV) procollagen (supplied by
Dr. M. Kurkinen, Rutgers Medical School, University of New
Jersey, Piscataway, NJ, USA); fibronectin (supplied by Dr. R.
Hynes, Center for Cancer Research, Massachusetts Institute of
Technology, Cambridge, MA, USA); rabbit stromelysin (supplied
by Dr. Z. Werb, University of California, San Francisco, CA,
USA); murine TIMP-1 (supplied by Dr. R. Khokha, London
Regional Cancer Centre, London, ON, Canada); rat plasmino-
gen-activator inhibitor-1 (rat PAI-1; supplied by Dr. Z.R.
Gelehrter, University of Michigan, Ann Arbor, MI, USA); uPA
(supplied by Dr. J. Degan, Children’s Hospital Research Foun-
dation, Cincinnati, OH, USA); and murine a2-antiplasmin (sup-
plied by Dr. P.A. Menoud, University of Geneva, Medical School,
Geneva, Switzerland) [31]. Unreferenced antibodies and cDNA
probes are cited in our previous publication [10].
Statistics
Results were compared using the Mann-Whitney U test. A P
value less than 0.05 was considered statistically significant.
RESULTS
Renal function
The antioxidant therapy had no significant effect on urinary
albumin excretion rates in rats fed a high-cholesterol diet (Table
1). Serum creatinine and final kidney weight, however, were
significantly lower in the hypercholesterolemic animals treated
with antioxidants. Creatinine clearance rates calculated on 24-
hour urine collections of spontaneously voided urine, expressed as
ml per minute per 300 g body wt, were not significantly different
in the three groups: 0.77 6 0.16 for the control group; 0.73 6 0.17
for the high-cholesterol group; and 0.91 6 0.35 for the high-
cholesterol/antioxidant group.
Lipid abnormalities
Rats fed a high-cholesterol diet developed significant hypercho-
lesterolemia and elevated renal levels of lipid peroxidation prod-
ucts compared with rats fed standard chow. These changes were
attenuated by antioxidant therapy (Table 2). Serum triglyceride
levels were not significantly different: 0.9 6 0.2 mmol/liter for the
control group; 1.3 6 0.6 mmol/liter for the high-cholesterol group;
and 1.4 6 0.4 mmol/liter for the high-cholesterol/antioxidant
group. Serum vitamin E levels were elevated in the hypercholes-
terolemic animals that were treated with antioxidants: 22 6 33
Table 1. Renal function
Group
Urinary albumin







gWeek 8 Week 12
Control group 0.3 6 0.4a 0.5 6 0.7a 285 6 22 49 6 4 1.4 6 0.1a
High-cholesterol group 15 6 15 23 6 16 301 6 24 52 6 4 2.0 6 0.4
High-cholesterol/antioxidant group 10 6 11 18 6 23 296 6 20 44 6 3a 1.5 6 0.2a
Results are means 6 1 SD. The body weight, serum creatinine and kidney weight are mean values at the time of sacrifice.
a P , 0.05 compared with the high-cholesterol group, by Mann-Whitney U test
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mmol/liter for the control group; 82 6 37 mmol/liter for the
high-cholesterol group; and 342 6 77 mmol/liter for the high-
cholesterol/antioxidant group.
Renal interstitial inflammation
The number of interstitial macrophages increased in rats fed
the high-cholesterol diet, a response that was not altered by the
addition of antioxidant therapy (Fig. 1).
Renal fibrosis
The total kidney collagen content was increased in rats fed a
high-cholesterol diet compared with control rats. The increase in
renal collagen was prevented by treatment with antioxidant
therapy (Fig. 2). Immunostaining confirmed the accumulation of
several matrix proteins in the renal interstitium of untreated
hypercholesterolemic rats. Compared with animals fed a normal
diet, hypercholesterolemic rats showed increased interstitial stain-
ing for the following average percentages of interstitial fields:
collagen I, 19%; collagen III, 12%; EDA1 fibronectin, 11%; and
tenascin, 16%. In antioxidant-treated hypercholesterolemic rats,
these numbers were decreased to: collagen I, 14%; collagen III,
1%; EDA1 fibronectin, 2%; and tenascin, 3%.
Renal gene expression in hypercholesterolemic rats
The renal expression of four extracellular matrix genes was
evaluated. Only procollagen a1(III) and a2(IV) levels were
significantly decreased by antioxidant therapy (Table 3). Antiox-
idant therapy significantly decreased renal TIMP-1 mRNA levels
to an average of 20% relative to the untreated animals (Table 3
and Fig. 3), while stromelysin levels were similar in both hyper-
cholesterolemic groups (Table 3). Immunostaining showed
TIMP-1 protein appearing de novo in the interstitium of the
hypercholesterolemic rats (Fig. 4). The overall intensity of inter-
stitial staining for TIMP-1 staining was decreased in the antioxi-
dant-treated group.
Antioxidant therapy significantly increased renal urokinase
Fig. 1. Interstitial macrophages, identified as cells expressing the ED-1
cytoplasmic antigen, for the control, high-cholesterol, and high-cholester-
ol/antioxidant groups. Results are means 6 1 SD. *P , 0.05 compared to
the high-cholesterol group.
Fig. 2. Total kidney collagen content for the control, high-cholesterol,
and high-cholesterol/antioxidant rats. Results are means 6 1 SD. *P ,
0.05 compared to the high-cholesterol group.








Control group 2 6 0.2a 122 6 8a
High-cholesterol group 19 6 5 144 6 8
High-cholesterol/antioxidant group 10 6 2a 125 6 9
Results are means 6 1 SD. “Renal products” are lipid peroxidation
products, in nanomoles of malondialdehyde per wet-weight gram of tissue,
measured at week 5.
a P , 0.05 compared with the high-cholesterol group, by Mann-Whitney
U test.







1. Extracellular matrix proteins
Procollagen a1(I) 0.9 NS
Procollagen a1(III) 0.6 0.035











The densitometric ratio compares the results of the high-cholesterol/
antioxidants group to those of the high-cholesterol group. Each ratio is
calculated from the mean densitometric scores after correction for any
RNA loading inequality. In other words, the corresponding ratio for the
closest ribosomal band (18s or 28s) is 1.0 for each gene evaluated.
Abbreviations are: TIMP-1, the tissue inhibitor of metalloproteinases;
uPA, urokinase-type plasminogen activator; PAI-1, plasminogen activator
inhibitor-1; TGF-b1, transforming growth factor b-1.
a Mann-Whitney U test analysis of individual densitometric results,
expressed as arbitrary units for each of the three animals in each group. P
, 0.05 was considered statistically significant.
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mRNA levels relative to the untreated hypercholesterolemic
group (Table 3 and Fig. 5). On immunostained slides, all tubules
appeared weakly positive for urokinase, and it was difficult to
discern a clear difference between the two groups. Renal mRNA
levels for the protease inhibitors PAI-1 and a2-antiplasmin were
similar in both hypercholesterolemic groups (Table 3).
Renal TGF-b1 mRNA levels were not decreased but rather
were significantly increased, to 50% above the levels observed in
the untreated group (Fig. 6). This observation was reproducible
on several different RNA blots. In the high-cholesterol group,
staining for bioactive TGF-b1 identified several positive intersti-
tial cells as well as some positive tubules (Fig. 7a). Immunostain-
ing for bioactive TGF-b1 shifted in the antioxidant-treated group
to more striking tubular staining, both a diffuse and a granular
cytoplasmic pattern (Fig. 7b).
DISCUSSION
In this study, combined antioxidant treatment with probucol
and vitamin E essentially prevented the early interstitial fibrosis
that developed in the untreated uninephrectomized rats with
severe hypercholesterolemia. These findings are consistent with
the reported efficacy of the antioxidants vitamin E or probucol in
attenuating tubulointerstitial disease in rats with chronic puromy-
cin aminonucleoside nephrosis [32–34]. Probucol therapy has
been reported to decrease serum cholesterol levels and the
severity of tubulointerstitial disease that develops in rats following
subtotal nephrectomy [35]. We chose combined high-dose therapy
with vitamin E and probucol to achieve maximal antioxidant
effect. In a recent study [22], we found that short-term treatment
of nephrotic rats with either vitamin E or probucol alone failed to
alter the degree of interstitial fibrosis that developed between
three and six weeks. We speculated that factors other than
hyperlipidemia were the predominant fibrogenic forces; however,
considering the alternative explanation, that the nephrotic rats
received suboptimal antioxidant treatment, we selected combined
Fig. 3. Renal mRNA levels of tissue inhibitor of metalloproteinases
(TIMP-1). By Northern blot analysis on the same autoradiograph, the
mean densitometric score for the high-cholesterol group was 1.0 6 0.7
arbitrary units, versus 0.2 6 0.1 arbitrary units for the high-cholesterol/
antioxidant group. This difference was statistically significant.
Fig. 4. Immunofluorescence photomicrograph illustrating (a) the de novo
expression of tissue inhibitor of metalloproteinases (TIMP-1) protein in
the kidney of a rat with diet-induced hypercholesterolemia, and (b) the
decrease in overall intensity of interstitial TIMP-1 staining in the
hypercholesterolemic animals treated with antioxidants. Magnification
3240.
Fig. 5. Renal mRNA levels of urokinase-type plasminogen activator
(uPA). The mean densitometric score for the high-cholesterol group by
Northern blot analysis on the same autoradiograph, 1.0 6 0.3 arbitrary
units, versus 2.1 6 1.2 arbitrary units for the high-cholesterol/antioxidant
group. This difference was statistically significant.
Fig. 6. Renal mRNA levels of transforming growth factor b-1 (TGF-b1).
By Northern blot analysis on the same autoradiograph, the mean densi-
tometric score for the high-cholesterol group was 1.0 6 0.3 arbitrary units,
versus 1.5 6 0.2 arbitrary units for the high-cholesterol/antioxidant group.
This difference was statistically significant.
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therapy for the present study. Whether single-drug therapy would
have been equally efficacious remains unknown. It should be
emphasized that the present study was terminated after three
months of hypercholesterolemia, when interstitial fibrosis is evi-
dent histologically but when it is not yet severe enough to have a
major effect on nephron function.
Why did antioxidant therapy prevent tubulointerstitial damage?
There are three possibilities. (1) The drugs themselves may have
had direct antifibrotic effects. Unfortunately, few data are cur-
rently available to support or refute this possibility. (2) The drugs
decreased the intrarenal generation of oxidized lipoproteins, with
subsequent fibrosis-preventing effects. In addition to their antiox-
idant effects, the combination of vitamin E and probucol signifi-
cantly reduced serum cholesterol levels, an effect likely due to the
modest lipid-lowering effects of probucol [36]. (3) The antioxidant
therapy did cause a significant reduction in serum cholesterol
levels. It is conceivable the the lowered cholesterol levels had a
beneficial effect that was independent of the level of lipid
peroxidation products within the kidney.
Renal lipid peroxidation products were normalized by antioxi-
dant therapy. Although oxidized LDL has been reported to have
monocyte chemotactic activity in vitro, the number of interstitial
macrophages was similar in both hypercholesterolemic groups,
which suggests that oxidized LDL is not a significant interstitial
monocyte chemoattractant in this model. Proteinuria has been
implicated in the pathogenesis of tubulointerstitial disease [37],
and hypercholesterolemia has been shown to aggravate glomeru-
lar damage [38, 39]. Nonetheless, in the present study antioxidant
therapy did not significantly reduce the severity of albuminuria in
the hypercholesterolemic animals. It seems reasonable to hypoth-
esize that the intrarenal oxidation of LDL generated bioactive
products that participated in the fibrogenic cascade. Binding of
oxidized LDL to receptors on tubular and/or interstitial cells
could be important. Although the evaluation of renal mRNA
levels was limited to the 12-week timepoint and may not reflect
earlier events, nonetheless, the results provide some insight into
possible fibrogenic pathways. Oxidized low-density lipoproteins
themselves may stimulate production of matrix proteins [40]. The
antioxidant-treated animals had significantly lower mRNA levels
for procollagens III and IV at 12 weeks. The reason for the lack
of significant effect by therapy on procollagen I levels is unclear,
but is supported by the observation that interstitial collagen I
immunostaining was similar in the untreated and treated hyper-
cholesterolemic animals (19% vs. 14% of interstitial fields, respec-
tively, showing increased interstitial deposits).
The results of the present study suggest that alterations in
matrix turnover also play an important role in the pathogenesis of
the interstitial fibrosis associated with severe hypercholesterol-
emia. In our previous study [10], TIMP-1 mRNA levels in rats fed
a high-cholesterol diet were found to be significantly increased to
140%, 270%, and 270% of control levels at 4, 8, and 12 weeks. The
present study observed a reversal of this change with antioxidant
supplementation, with renal TIMP-1 mRNA levels reduced to
20% of untreated levels and a similiar reduction in immunode-
tectable TIMP-1 protein. To the best of our knowledge, the ability
of oxidized LDL to directly stimulate TIMP-1 production has not
been investigated. It is perhaps relevant that overexpression of
TIMP-1 has been reported in atherosclerotic plaques, although
metalloproteinase expression was also up-regulated in the same
areas, and a net increase in gelatinolytic activity was reported [41].
Our study also suggests that impaired intrarenal uPA and
plasmin activity is a feature of tubulointerstitial disease and that
this imbalance can be reversed by antioxidant therapy. Urokinase-
type plasminogen activator is produced constitutively by tubular
cells [42]. In our original study in uninephrectomized hypercho-
lesterolemic rats, down-regulation of renal uPA mRNA levels was
a persistent feature, with levels sustained at 40% relative to
control levels throughout weeks 4, 8, and 12. The most abundant
intrarenal plasminogen activator inhibitor, PAI-1 [43], was not
down-regulated to offset this change. Taken together, these
findings predict a significant reduction in intrarenal urokinase
activity and plasmin generation during the phase of active inter-
stitial fibrosis. Treatment of hypercholesterolemic animals with
antioxidant therapy attenuated this decrease in uPA expression.
Renal uPA mRNA levels in the high-cholesterol/antioxidant
group were twice those in the untreated group. Both PAI-1 and
a2-antiplasmin levels were similar in both hypercholesterolemic
groups; we measured a2-antiplasmin levels in response to the
recent report of high intrarenal levels of this uPA inhibitor [31].
The ability of oxidized LDL to inhibit uPA production has not
been investigated in vitro. The plasmin activator/plasmin pathway
Fig. 7. Immunofluorescence photomicrographs illustrating expression of
transforming growth factor b-1 (TGF-b1) in the tubules and interstitium
of rats with hypercholesterolemia. (a) In rats with diet-induced hypercho-
lesterolemia, several TGF-b1–positive cells can be observed in the inter-
stitium. (b) In hypercholesterolemic rats treated with antioxidants, protein
expression of TGF-b1 shifted toward a predominantly tubular pattern.
Magnification 3260.
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has also been implicated in atherogenesis, although overexpres-
sion of both plasminogen activators and inhibitors has been
reported [44–46].
The surprising result of the present study is the pattern of
TGF-b1 expression. In our initial study, we had speculated that
oxidized LDL–stimulated TGF-b1 production could be a unifying
hypothesis to explain all of the molecular features of tubulointer-
stitial disease associated with severe hypercholesterolemia, such
as increased matrix gene and TIMP expression and decreased
uPA expression [40]. In vitro studies, however, are conflicting. In
one study [47], oxidized LDL failed to stimulate TGF-b1 expres-
sion in cultured endothelial cells. However, Ding and colleagues
[48] have recently reported enhanced expression of TGF-b1 by
cultured human glomerular epithelial cells in the presence of
oxidized LDL. It remains difficult to explain why antioxidant
therapy should increase renal TGF-b1 expression. Vitamin E has
been reported to induce a TGF-b1–dependent antiproliferative
effect in vitro, but this appears to be at post-transcriptional levels
[49, 50].
Before concluding that TGF-b1 does not have fibrosis-promot-
ing effects in rats with hypercholesterolemia, a few additional
points need to be raised. (1) The pattern of expression of bioactive
TGF-b1 protein was changed by antioxidant therapy. Fewer
positive interstitial cells were observed, and most of the protein
was localized to tubular cells in the antioxidant-treated group.
Perhaps TGF-b1 produced by interstitial myofibroblasts and/or
macrophages is most relevant to interstitial fibrosis, as previously
suggested [51]. (2) The ability of TGF-b1 to initiate fibrogenic
signals depends on the absence of its inhibitors and the availability
of dimerizing type I and II receptors [52], factors that were not
investigated in the present study.
Is there another molecule whose expression is stimulated by
oxidized LDL that might account for the observed changes in the
expression of TIMP-1 and uPA in the kidneys of the hypercho-
lesterolemic rats? Several factors in addition to TGF-b1 have
been identified that may stimulate TIMP-1 expression, including:
epidermal growth factor; transforming growth factor-a; tumor
necrosis factor; interleukins-1, -6, and -10; oncostatin M; throm-
bin; platelet-derived growth factors; and phorbol esters [53–55].
Very few factors, except drugs such as colchicine and vinblastine,
have been reported to decrease uPA expression [21, 54, 56]. From
the literature, we were only able to identify two factors that
increase TIMP-1 and decrease uPA expression—lipopolysaccha-
ride and glucocorticoids—and neither of these can be readily
implicated in the current study.
In summary, the present study demonstrates that the renal
interstitial fibrosis that develops insidiously in uninephrectomized
rats with severe hypercholesterolemia can be reversed with anti-
oxidant therapy combining vitamin E and probucol. Studies of
renal gene expression demonstrate that antioxidant therapy is
associated with lower mRNA levels for genes encoding extracel-
lular matrix proteins and TIMP-1, and higher uPA mRNA levels.
We speculate that intrarenal oxidation of LDL may elicit a
fibrogenic response in the renal interstitium, leading to both an
increase matrix synthesis and a decrease in matrix degradation.
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